Clinical trial Recruiting at 1 site Observational Ages 18 and up

Antibiotic approaches for Stenotrophomonas maltophilia pneumonia in ICU patients

Official title: Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients

Run by Centre Hospitalier de Saint-Denis · NCT07052604 · Data updated 2026-11-12

This study tests whether using one antibiotic versus two, and whether treating for 7 days versus 14 days, helps adults on ventilators in the ICU with Stenotrophomonas maltophilia pneumonia survive and avoid recurrence.

More Ventilator Associated Pneumonia trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment300 (estimated)
SponsorCentre Hospitalier de Saint-Denis
Academic / other
Locations1 site (Saint-Denis, France)
StatusRecruiting
StartedDecember 15, 2023
Main results expectedSeptember 15, 2025
Study endsSeptember 15, 2025
Registry record updatedJuly 4, 2025
Trial IDNCT07052604 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (age 18 or older) who were intubated and mechanically ventilated in the medical ICU at Centre Hospitalier de Saint-Denis between January 1, 2018 and December 31, 2023 with ventilator-associated pneumonia caused by Stenotrophomonas maltophilia.

Probably not a fit

Children, non‑ventilated patients, patients with pneumonia caused by other organisms, and anyone who declined use of their data are not included and would not directly benefit from this analysis.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective observational analysis of adult patients intubated in a medical ICU at Centre Hospitalier de Saint-Denis between January 1, 2018 and December 31, 2023 who had ventilator‑associated pneumonia due to Stenotrophomonas maltophilia. The analysis compares outcomes between patients treated with a single antibacterial agent versus combination therapy and between treatment durations of 7 days versus 14 days. Key outcomes include survival, recurrence of pneumonia, and antibiotic resistance patterns of the isolated bacteria. Findings will be based on chart review and microbiology data from a single center.

Why it matters

Potential benefit: If patterns emerge, the results could help clinicians choose an antibiotic strategy and treatment length that improve survival and reduce recurrence in this difficult-to-treat infection.

How similar studies have gone: Previous evidence on S. maltophilia pneumonia is limited and mainly observational, and there is no definitive randomized evidence that combination therapy or longer treatment duration is superior.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adult patients (age ≥ 18 years)
* Hospitalized in Medical Intensive Care Unit between January 1, 2018, and December 31, 2023
* Intubated and mechanically ventilated
* Diagnosed with ventilator-associated pneumonia caused by Stenotrophomonas maltophilia

Exclusion Criteria:

* Patients under 18 years old
* Patients who refuse the use of their data for research purposes

Where it's running

  • Centre Hospitalier de Saint-Denis
    Saint-Denis, France, France
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.